[G23-20] Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31

Last updated 05.10.2023

Project no.:
G23-20

Commission:
Commission awarded on 09.08.2023 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Airways and respiratory system

Note:

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.

Federal Joint Committee (G-BA)

05-10-2023 A G-BA decision was published.
G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form